Takeda Pharmaceutical Company Limited
TAKWI
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.62B | 29.99B | 30.08B | 30.24B | 30.27B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.62B | 29.99B | 30.08B | 30.24B | 30.27B |
| Cost of Revenue | 10.42B | 10.50B | 10.32B | 10.48B | 10.32B |
| Gross Profit | 19.20B | 19.49B | 19.76B | 19.77B | 19.95B |
| SG&A Expenses | 7.21B | 7.29B | 7.25B | 7.23B | 7.27B |
| Depreciation & Amortization | 3.14B | 3.19B | 3.18B | 3.19B | 1.99B |
| Other Operating Expenses | 511.16M | 103.72M | 404.46M | 288.59M | -175.43M |
| Total Operating Expenses | 25.91B | 25.79B | 25.95B | 25.88B | 24.24B |
| Operating Income | 3.71B | 4.20B | 4.12B | 4.37B | 6.03B |
| Income Before Tax | 703.04M | 1.32B | 1.15B | 1.53B | 1.77B |
| Income Tax Expenses | 442.33M | 355.19M | 437.74M | 165.33M | -152.99M |
| Earnings from Continuing Operations | 260.71 | 959.94 | 710.88 | 1.37K | 1.93K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.41M | -1.34M | -1.41M | -1.20M | -1.14M |
| Net Income | 259.30M | 958.61M | 709.46M | 1.37B | 1.93B |
| EBIT | 3.71B | 4.20B | 4.12B | 4.37B | 6.03B |
| EBITDA | 8.10B | 8.62B | 8.53B | 8.82B | 10.52B |
| EPS Basic | 0.17 | 0.61 | 0.45 | 0.87 | 1.22 |
| Normalized Basic EPS | 1.11 | 1.28 | 1.27 | 1.38 | 2.03 |
| EPS Diluted | 0.16 | 0.60 | 0.44 | 0.85 | 1.21 |
| Normalized Diluted EPS | 1.10 | 1.27 | 1.26 | 1.37 | 2.01 |
| Average Basic Shares Outstanding | 6.31B | 6.31B | 6.32B | 6.31B | 6.29B |
| Average Diluted Shares Outstanding | 6.33B | 6.36B | 6.37B | 6.35B | 6.34B |
| Dividend Per Share | 1.32 | 1.30 | 1.30 | 1.29 | 1.29 |
| Payout Ratio | 803.40% | 217.56% | 277.06% | 143.72% | 101.03% |